Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. aglyc

AGLYC

The First In Vitro Diagnostic Device for the Early Detection of Cardiac Ischemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 AGLYC project word cloud

Explore the words cloud of the AGLYC project. It provides you a very rough idea of what is the project "AGLYC" about.

diagnosis    progression    plasma    cagr    oxygen    irreversible    medical    tissues    small    31    global    either    medtech    accounted    ischemic    model    don    90    market    women    2015    biomarkers    2017    accounting    damage    business    2016    device    jobs    diagnostic    usa5eu    hrs    globe    trl6    almost    detect    103m    biomarker    care    risk    rapid    prevent    quantification    stage    stratification    advantages    detects    blood    97    man    2024    sensitivity    diagnostics    deaths    36m    647m    ivd    causing    ischemia    supply    estimate    ebitda    sublicensed    cvd    61    glycardial    19m    aglyc    circulating    demonstrates    successful    organ    6    company    onset    84    markers    reversible    vitro    right    39    cardiac    fact    commercialization    cardiovascular    restriction    completion    levels    prognosis    70m    detection    min    detecting    smei    obviously    tissue    useless    2023    point    heart    necrosis    apo    lab    morbidity    patients    competitive    glyc    poc    pharmaceutical    effectiveness    gt    sublicense    shortage    death    co    diseases   

Project "AGLYC" data sheet

The following table provides information about the project.

Coordinator		 GLYCARDIAL DIAGNOSTICS, SL 

Organization address
address: CALLE BALDIRI REIXAC 48 - PLANTA 1 PUERTA B04 PARC CIENTIFIC DE BARCELONA TORRE R
city: BARCELONA
postcode: 8028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Spain [ES]
 Project website http://www.glycardial.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-07-01   to  2018-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCARDIAL DIAGNOSTICS, SL ES (BARCELONA) coordinator 50˙000.00

Map

 Project objective

Cardiovascular diseases (CVD) are the leading cause of death/morbidity across the globe, accounting for 31% of all deaths in 2015. Early detection of ischemia (restriction in blood supply to tissues, causing oxygen shortage) is essential to prevent the progression of heart damage, but right now, we don’t have any biomarkers for the early detection of cardiac ischemia. In fact, almost 90% of the available in vitro diagnostic (IVD) methods are based on the quantification of markers of necrosis, an advanced stage of organ damage. Obviously, these methods are useless for the early detection of ischemic damage.

AGLYC is an IVD device based on the rapid quantification circulating plasma Apo J-Glyc levels as a novel biomarker for the diagnosis, prognosis and risk stratification of ischemia and ischemic tissue damage. AGLYC demonstrates a 97% sensitivity in detecting the presence of cardiac ischemia; market state of the art is 39%. It also detects ischemic damage at an early and reversible phase (30 min after ischemia onset); state of the art can only detect ischemia 6 hrs after its onset when tissue damage is irreversible. We are currently at TRL6 having the competitive advantages of high sensitivity, early detection and cost effectiveness.

The Global IVD market accounted for $61,103M in 2016 and is estimated to reach $84,647M by 2023, growing at a CAGR of 4.6% from 2017-2023. We have estimated a lab-based target market of >70M patients (USA5EU) and a Point of Care (POC) target market of >36M patients (USA5EU). Our main business model will be a sublicense model: a lab-based test will be developed and sublicensed to either a medical device company (like MedTech) or to a pharmaceutical company for the co-development and commercialization of the POC device. GlyCardial Diagnostics, S.L. is a small company of 4 (3 women, 1 man) but with the successful completion of the SMEI Phase 1 and 2 we estimate an EBITDA of around €19M, creating 10 new jobs by 2024.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AGLYC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AGLYC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More